Home

26.01.2012	Boehringer Ingelheim Moves into Phase III for its Head and Neck Cancer Trial Programme for Afatinib* - For non-US Media Only
26.01.2012	Boehringer Ingelheim launches ‘Lean-to-Clinic’ program for fast drug product supply
07.12.2011	Winners of the Making More Health competition bring fresh innovation to solving problems in health
01.12.2011	Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab
17.11.2011	Boehringer Ingelheim's Anticoagulant PRADAX® Awarded Prestigious Prix Galien Canada for Most Innovative Product in 2011

Help